The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia
The spleen in Sickle Cell Anemia and Sickle Cell Thalassemia is usually enlarged in the first years of life but the immune protection provided is considered insufficient. In homozygous Sickle cell patients the spleen usually developed recurrent infarcts and after the first decade of age become fibrotic. Acute splenic sequestration is also frequent in those patients and this is considered as an indication for splenectomy.
In comparison in Sickle cell thalassemia patients, hypersplenism is more frequent.
The purpose of this study is to compare the clinical and laboratory issues related to the spleen in two groups of Sickle cell patients.
Sickle Cell Anemia
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications.|
- Clinical events and abnormal laboratory results [ Time Frame: One year ] [ Designated as safety issue: No ]
|Study Start Date:||February 2009|
|Study Completion Date:||August 2010|
|Primary Completion Date:||August 2010 (Final data collection date for primary outcome measure)|
Sickle Cell Patients
Patients with homozygous Sickle Cell Anemia
Sickle Cell Thalassemia
Patients with Sickle Cell Thalassemia
Clinical and laboratory characteristics related to the spleen in SCA patients will be studied.
Two groups of patient will be compared, a group of Sickle cell patients (Homozygous) and a second group of patients with Sickle cell beta thalassemia.
In those patients that splenectomy was performed the incidence of infections will be recorded besides the indications for splenectomy and the incidence of thrombotic events or thrombocytosis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00971698
|Pediatric Hematology Unit and Pediatric Dpt B - HaEmek Medical Center|
|Afula, Israel, 18101|